---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-344978"
form_type: "8-K"
ticker: "AARD"
cik: "0001774857"
company_name: "Aardvark Therapeutics, Inc."
filed_at: "2026-08-11T21:05:23+00:00"
generated_at: "2026-08-11T21:06:09.920117+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aardvark reports Q2 net loss $14.4M; ARD-101 clinical hold, HERO/OLE terminated

## Summary
- Cash $73.9M as of Jun 30, 2026 vs $91.2M at Mar 31; funds operations into late 2027.
- Q2 R&D $10.5M vs $13.1M YoY; G&A $4.6M vs $2.7M; net loss $14.4M both periods.
- FDA full clinical hold on ARD-101 IND in May 2026; HERO and OLE trials terminated June 2026.
- Assessing unblinded HERO and OLE data in Q3 2026 to determine next steps for ARD-101.
- Active FDA discussions to resolve clinical hold; workforce reduction in June 2026.

## SEC filing metadata
- accession: 0001193125-26-344978
- form_type: 8-K
- ticker: AARD
- cik: 0001774857
- company_name: Aardvark Therapeutics, Inc.
- filed_at: 2026-08-11T21:05:23+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1774857/000119312526344978/0001193125-26-344978-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1774857/000119312526344978/ck0001774857-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-344978
- JSON: https://secwatch.observer/filing/0001193125-26-344978.json
- Plain text: https://secwatch.observer/filing/0001193125-26-344978.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.